The fatal crash occurred in China's Yunnan province on Saturday, with investigations into the collision ongoing. Source: China News Network
The fatal crash occurred in China's Yunnan province on Saturday, with investigations into the collision ongoing. Source: China News Network
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO, March 04, 2021 (GLOBE NEWSWIRE) -- Points International Ltd. (TSX: PTS) (Nasdaq: PCOM) (“Points” or the “Company”), the global leader in powering loyalty commerce, is pleased to announce that it has entered into a revised agreement with a syndicate of underwriters led by Acumen Capital Finance Partners Limited (the “Underwriters”) to increase the size of the previously announced bought deal financing. Pursuant to the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, an aggregate of 1,467,400 common shares of Points (the “Common Shares”) at a price of $18.75 per Common Share (the “Offering Price”) for aggregate gross proceeds to the Company of approximately $27.5 million (the “Offering”). The Company has granted the Underwriters an over-allotment option exercisable at any time up to 30 days following the closing of the Offering, to purchase up to an additional 220,110 Common Shares at the Offering Price. In the event that the over-allotment option is exercised in full, the gross proceeds of the Offering will be approximately $31.6 million. The Company expects to use the net proceeds to fund the advancement of its product road map and its data analytics, marketing automation, and machine learning capabilities. The net proceeds may also be used to fund future growth opportunities and to accelerate the Company’s business development pipeline. The Common Shares will be offered by way of short form prospectus, qualifying the Common Shares for distribution in all of the Provinces of Canada, and in the United States by way of private placement pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended, and outside of Canada and the United States on a private placement or equivalent basis. The closing of the Offering is scheduled to occur on or about March 29, 2021, and is subject to customary closing conditions, including receipt of applicable regulatory and Toronto Stock Exchange and NASDAQ Capital Market approvals. About Points Points, (TSX: PTS) (Nasdaq: PCOM) is a trusted partner to the world’s leading loyalty programs, leveraging its unique Loyalty Commerce Platform to build, power, and grow a network of ways members can get and use their favourite loyalty currency. Our platform combines insights, technology, and resources to make the movement of loyalty currency simpler and more intelligent for nearly 60 reward programs worldwide. Founded in 2000, Points is headquartered in Toronto with teams operating around the globe. For more information, visit Points.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares in the United States nor shall there be any sale of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Common Shares offered under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or the securities laws of any state of the United States. Accordingly, the Common Shares offered under the Offering may not be offered or sold in the United States or to U.S. persons unless an exemption from registration is available. Caution Regarding Forward-looking Statements This press release contains or incorporates forward-looking statements within the meaning of United States securities legislation, and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”). These forward-looking statements include or relate to but are not limited to, among other things, the closing of the Offering and the intended use of net proceeds of the Offering. These statements are not historical facts but instead represent only Points’ expectations, estimates and projections regarding future events. Although Points believes the expectations reflected in such forward-looking statements are reasonable, such statements are not guarantees of future performance and are subject to important risks and uncertainties that are difficult to predict. Certain material assumptions or estimates are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Undue reliance should not be placed on such statements. In particular, uncertainty around the duration and scope of the COVID-19 pandemic and the impact of the pandemic and actions taken in response on global and regional economies, economic activity, and all elements of the travel and hospitality industry may have a significant and materially adverse impact on our business. Key assumptions in respect of the Offering include, but are not limited to, assumptions that the Offering will close as expected and that Points will obtain regulatory and third party approvals for the Offering and that the conditions to closing the Offering will be satisfied. In addition, the risks, uncertainties and other factors that may impact the results expressed or implied in such forward-looking statements include, but are not limited to: (i) airline or travel industry disruptions, such as an airline insolvency and continued airline consolidation; (ii) our dependence on a limited number of large clients for a significant portion of our consolidated revenue; (iii) our reliance on contractual relationships with loyalty program partners that are subject to termination and renegotiation; (iv) our exposure to significant liquidity risk if we fail to meet contractual performance commitments; (v) our ability to convert our pipeline of prospective partners or launch new products with new or existing partners as expected or planned; (vi) our dependence on various third-parties that provide certain solutions in our Platform Partners segment that we market to loyalty program partners; (vii) the fact that our operations are conducted in multiple jurisdictions and in multiple currencies and as such dramatic fluctuations in exchange rates of the foreign currencies can have a dramatic effect on our financial results and (viii) the risk of an event of default under our senior secured credit facility. These and other important risk factors that could cause actual results to differ materially are discussed in Points’ annual information form, Form 40-F, annual and interim management's discussion and analysis (“MD&A”), and annual and interim financial statements and the notes thereto. These documents are available at www.sedar.com and www.sec.gov. The forward-looking statements contained in this press release are made as at the date of this release and, accordingly, are subject to change after such date. Except as required by law, Points does not undertake any obligation to update or revise any forward-looking statements made or incorporated in this press release, whether as a result of new information, future events or otherwise. Investor Relations Contact Sean Mansouri, CFA or Cody Slach Gateway Investor Relations 1-949-574-3860 IR@points.com
Up to 100,000 undocumented farm workers would be given a pass to stay in Australia under recommendations made to the Morrison government.A major report into Australia's agricultural labour crisis has called for sweeping changes to fix the shortage and exploitation of workers in the sector.
Cash will disappear in Australia faster than experts predicted, a new report has found.
The Victorian government will "partly privatise" VicRoads and hand over the registration and licensing side of the agency to a private company.Treasurer Tim Pallas says the joint venture will likely be a 40-year arrangement and the company will be responsible for upgrading VicRoads' IT system.
VPC Impact Acquisition Holdings II (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, today announced the pricing of its initial public offering of 22,500,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market, or Nasdaq, and trade under the ticker symbol "VPCBU" beginning March 5, 2021. Each unit consists of one Class A ordinary share and one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "VPCB" and "VPCBW," respectively.
VPC Impact Acquisition Holdings III, Inc. (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, today announced the pricing of its initial public offering of 22,500,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange, or the NYSE, and trade under the ticker symbol "VPCCU" beginning March 5, 2021. Each unit consists of one share of Class A common stock and one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A common stock and warrants are expected to be listed on the NYSE and trade under the symbols "VPCC" and "VPCCW," respectively.
It's been over three years since Katherine Kirk last won on the LPGA Tour, but the 39 year-old Australian finds herself firmly in the mix at the Drive On Championship.Kirk, who last won at the 2017 Thornberry Classic, shot an impressive three-under 69 to be just two shots behind American leaders Nelly Korda, Jennifer Kupcho and Austin Ernst after the opening round of the tournament.
Inside, Kazuyoshi Sasaki carefully dials his late wife Miwako's cellphone number, bending his large frame and cradling the handset. He explains how he searched for her for days after the devastating earthquake and tsunami a decade ago, visiting evacuation centres and makeshift morgues, returning at night to the rubble of their home. Sasaki's wife was one of nearly 20,000 people in northeastern Japan killed by the disaster that struck on March 11, 2011.
An investigation into Melissa Caddick's assets has led to a development in her case.
An already challenging life combining full-time work as a doctor with mothering two autistic sons was turned upside down for Meenakshi Mourya when the pandemic hit India. For almost a month as cases spiked last year, Mourya said she could not spend time with her children as she worked long and gruelling hours treating a flood of patients. "I was so emotionally down at that time...patients were dying in front of me," she said, visibly emotional as she spoke to Reuters in the home she shares with her husband, also a doctor, and their four and nine-year olds, who need help to eat and find it hard to communicate.
The United States Court of Appeals for the Second Circuit today affirmed multiple findings of civil contempt against disbarred attorney Steven Donziger, effectively bringing to a close his campaign to profit from the fraudulent Ecuadorian judgment he procured in violation of the Racketeer Influenced and Corrupt Organizations ("RICO") Act.
Alabama has extended for another month an order mandating residents to wear face masks, breaking with Mississippi and Texas as the issue again becomes the focus of national debate.Alabama's mask order, which had been due to expire on Friday, will now stay in effect until April 9, Republican Governor Kay Ivey says.
Indigenous Australians are extremely vulnerable to COVID-19 and doctors fear vaccine hesitancy could increase the risks.
(Bloomberg) -- China set its economic growth target at above 6% for the year as it rebounds strongly from the pandemic-induced slump.The government aims to add more than 11 million urban jobs this year and plans a budget deficit of 3.2% of gross domestic product, Premier Li Keqiang said Friday at the opening of the National People’s Congress.China’s economy was the only major one in the world to expand last year, aided by the central bank’s injections of liquidity to support businesses, extra fiscal spending on infrastructure and the quick control of coronavirus outbreaks domestically. Its V-shaped recovery alongside a recession in the U.S. and elsewhere puts it on course to become the world’s largest economy by 2028, two years earlier than expected, according to projections by several banks including Nomura Holdings Inc.What to Watch as China Rolls Out Economic Plan to Overtake U.S.Economists predict the economy will expand 8.4% this year, partly due to the low base from last year. Alongside that recovery has been a build-up in debt and worries about asset bubbles, fueling expectations that policy makers will withdraw the monetary and fiscal stimulus unleashed during the pandemic last year.This year’s meeting of the NPC, China’s main legislature, has added significance because of the release of a new five-year plan covering 2021-2025. Some of the key goals already outlined include strenghthening consumer demand, investing in hi-tech industries, and addressing long-term challenges such as an aging population.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Please replace the graphic with the accompanying corrected graphic.
Elections for Hong Kong's legislature will likely be deferred for a second year to September 2022 as Beijing plans a major overhaul of the city's electoral system, the South China Morning Post reported on Friday, citing unnamed sources. The delay, if confirmed, would be in line with a new effort by Beijing to ensure "patriots" are in charge of the global financial hub, potentially the biggest blow to the city's democratic hopes since its handover from British rule in 1997. Zhang Yesui, a spokesman for the National People's Congress, said on Thursday it had the constitutional power to "improve" Hong Kong's system and a draft decision would be discussed during the annual parliamentary session which opens on Friday.
SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $31.00 per share. The public offering was upsized from the previously announced size of 4,000,000 shares of its common stock. All shares of common stock are being offered by Nurix. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $139.5 million. In addition, Nurix has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 9, 2021, subject to the satisfaction of customary closing conditions. J.P. Morgan, Piper Sandler and Stifel are acting as the joint bookrunning managers for the proposed offering. RBC Capital Markets and Needham & Company are acting as the lead managers for the proposed offering. A registration statement relating to the sale of these securities has been filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at email@example.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or via email at firstname.lastname@example.org; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or via email at email@example.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Nurix Therapeutics, Inc. Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management and include, but are not limited to, statements regarding the expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities, and Nurix’s ability to complete the offering. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Nurix believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Nurix’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, and the risks and uncertainties described under the heading “Risk Factors” in documents Nurix files from time to time with the SEC, including Nurix’s Annual Report on Form 10-K filed with the SEC on February 16, 2021, the preliminary prospectus for this offering included as part of the registration statement on Form S-1 related to this offering filed with the SEC on March 2, 2021, and its future periodic reports to be filed with the SEC. These forward-looking statements speak only as of the date of this press release, and Nurix undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Investor ContactJason Kantor, Ph.D.Nurix Therapeutics, Inc.firstname.lastname@example.org Media ContactElizabeth Wolffe, Ph.D.Wheelhouse Life Science Advisorslwolffe@wheelhouselsa.com
AHCO earnings call for the period ending December 31, 2020.
May I now hand you over to Polina Ugryumova, Director of Investor Relations, who will lead you through this conference. Before we start, I must remind you that, except historical information, any comments made during this call may constitute forward-looking statements. Important factors could cause our actual results to differ materially from those contained in our projections or forward-looking statements.
Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of 3D Systems Corporation ("3D Systems" or the "Company") (NYSE: DDD) investors concerning the Company’s possible violations of the federal securities laws.